1. Home
  2. SPT vs EVO Comparison

SPT vs EVO Comparison

Compare SPT & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SPT

Sprout Social Inc

HOLD

Current Price

$7.49

Market Cap

327.6M

Sector

Technology

ML Signal

HOLD

Logo Evotec SE

EVO

Evotec SE

HOLD

Current Price

$3.06

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SPT
EVO
Founded
2010
1993
Country
United States
Germany
Employees
N/A
4553
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
327.6M
1.1B
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
SPT
EVO
Price
$7.49
$3.06
Analyst Decision
Buy
Strong Buy
Analyst Count
8
1
Target Price
$11.75
$7.00
AVG Volume (30 Days)
1.4M
47.1K
Earning Date
05-07-2026
04-08-2026
Dividend Yield
N/A
N/A
EPS Growth
32.11
N/A
EPS
N/A
N/A
Revenue
$457,547,000.00
N/A
Revenue This Year
$8.86
$1.37
Revenue Next Year
$8.04
$10.05
P/E Ratio
N/A
N/A
Revenue Growth
12.72
N/A
52 Week Low
$4.92
$2.31
52 Week High
$22.59
$4.42

Technical Indicators

Market Signals
Indicator
SPT
EVO
Relative Strength Index (RSI) 65.40 56.03
Support Level $5.94 $2.88
Resistance Level $11.50 $3.75
Average True Range (ATR) 0.41 0.07
MACD 0.06 0.01
Stochastic Oscillator 98.06 89.58

Price Performance

Historical Comparison
SPT
EVO

About SPT Sprout Social Inc

Sprout Social Inc develops a cloud software that brings together social messaging, data and workflows in a unified system of record, intelligence, and action. It has a centralized, secure and powerful platform that can scale horizontally across an organization to drive maximum business value. The firm generates majority revenue from software subscriptions. Geographically, the company operates in Americas, EMEA, and Asia Pacific, of which it derives maximum revenue from Americas.

About EVO Evotec SE

Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.

Share on Social Networks: